A worker in a polyvinyl chloride factory with rapidly progressive diffuse cutaneous scleroderma was treated with the humanized monoclonal antibody (Mab) CAMPATH-1H. Treatment was followed by rapid and substantial improvement in skin score, which was maintained during followup without additional therapy. The mode of action of CAMPATH-1H and its relationship to clinical improvement are discussed
Campath-1G is an immunosuppressive monoclonal antibody directed against human lymphocytes. Its effec...
Systemic sclerosis, a subcategory of scleroderma, is a rare autoimmune disease that affects the skin...
From 1991-2002, we treated 58 patients with multiple sclerosis (MS) using the humanised monoclonal a...
A worker in a polyvinyl chloride factory with rapidly progressive diffuse cutaneous scleroderma was ...
BACKGROUND: Standard therapy for severe, immune mediated, ocular inflammation has significant side e...
A 41-year-old woman with active, seropositive erosive rheumatoid arthritis was treated with the huma...
CAMPATH-1H is a humanised mAb directed against lymphocytes. This mAb has been used to treat patients...
Six patients with autoimmune thrombocytopenic purpura (three of whom had CLL/NHL and one previous Ho...
In a pilot study, seven patients with multiple sclerosis were treated with CAMPATH-IH which targets ...
Campath 1-H (Alemtuzumab) is a humanised monoclonal antibody which targets the CD52 antigen, a low m...
Objective. To evaluate CAT-192, a recombinant human antibody that neutralizes transforming growth fa...
The recent licensing of CAMPATH-1H (alemtuzumab) for the treatment of patients with refractory chron...
A genetically reshaped human IgG1 monoclonal antibody (CAMPATH-1H) was used to treat two patients wi...
The elective treatment of patients with multiple sclerosis, using a humanized anti-leukocyte (CD52) ...
The elective treatment of patients with multiple sclerosis, using a humanized anti-leukocyte (CD52) ...
Campath-1G is an immunosuppressive monoclonal antibody directed against human lymphocytes. Its effec...
Systemic sclerosis, a subcategory of scleroderma, is a rare autoimmune disease that affects the skin...
From 1991-2002, we treated 58 patients with multiple sclerosis (MS) using the humanised monoclonal a...
A worker in a polyvinyl chloride factory with rapidly progressive diffuse cutaneous scleroderma was ...
BACKGROUND: Standard therapy for severe, immune mediated, ocular inflammation has significant side e...
A 41-year-old woman with active, seropositive erosive rheumatoid arthritis was treated with the huma...
CAMPATH-1H is a humanised mAb directed against lymphocytes. This mAb has been used to treat patients...
Six patients with autoimmune thrombocytopenic purpura (three of whom had CLL/NHL and one previous Ho...
In a pilot study, seven patients with multiple sclerosis were treated with CAMPATH-IH which targets ...
Campath 1-H (Alemtuzumab) is a humanised monoclonal antibody which targets the CD52 antigen, a low m...
Objective. To evaluate CAT-192, a recombinant human antibody that neutralizes transforming growth fa...
The recent licensing of CAMPATH-1H (alemtuzumab) for the treatment of patients with refractory chron...
A genetically reshaped human IgG1 monoclonal antibody (CAMPATH-1H) was used to treat two patients wi...
The elective treatment of patients with multiple sclerosis, using a humanized anti-leukocyte (CD52) ...
The elective treatment of patients with multiple sclerosis, using a humanized anti-leukocyte (CD52) ...
Campath-1G is an immunosuppressive monoclonal antibody directed against human lymphocytes. Its effec...
Systemic sclerosis, a subcategory of scleroderma, is a rare autoimmune disease that affects the skin...
From 1991-2002, we treated 58 patients with multiple sclerosis (MS) using the humanised monoclonal a...